PharmAla (MDXXF) Biotech Holdings has publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. “Commencing in late 2025 and continuing into Q1 2026 we have taken major steps towards the development of our novel molecules and look to continue this momentum throughout the remainder of fiscal 2026 with the goal of commencing our Phase 2a/b clinical trial in Australia,” said Nick Kadysh, CEO. “While we have been prioritizing our development, we have continued to see great traction in demand for our LaNeo MDMA, which has continued to grow our pipeline of clinical trial sales. With the approval of reimbursement for medical treatments using LaNeo MDMA in Australia, both by private medical insurers and by the Australian Department of Veterans Affairs, we believe that this trend will only continue.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXXF:
- Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial
- PharmAla Biotech Contracts UK CDMO for ALA-002 Manufacturing
- PharmAla contracts with UK-based CMO for ALA-002 manufacturing
- Psychedelic: Atai Beckley granted U.S. patent for EMP-01
- PharmAla Biotech Advances with Australian-Made MDMA Capsules